(Reuters)—AbbVie Inc. and ELi Lilly & Co. are facing fresh delays in the approval of their respective rheumatoid arthritis (RA) drugs for treating the chronic skin disease eczema as the U.S. health regulator assesses the new class of treatment over safety concerns. The treatment, called Janus kinase inhibitors (jakinibs), blocks inflammation-causing enzymes known as Janus…
Search results for: baricitinib
Manifestations of JIA: JIA-Associated Uveitis, sJIA & Lung Involvement in sJIA
JIA can manifest in a variety of ways. Experts discuss the implications of uveitis, systemic disease and lung involvement in sJIA.
COPA Syndrome: What Do We Know About This Rare Disease?
ACR CONVERGENCE 2020—Tiphanie Phillips Vogel, MD, PhD, assistant professor of pediatrics and internal medicine at Baylor College of Medicine, Houston, moderated the session on COPA syndrome, which drew 324 attendees on a Sunday morning. This rare genetic cause of immune dysregulation can present like anti-neutrophil cytoplasmic antibody (ANCA) associated vasculitis, lupus, lupus nephritis or rheumatoid…
Upadacitnib for RA: Researchers Compared Upadacitinib with Placebo & Adalimumab in Patients with RA & an Inadequate Response to Methotrexate
In phase 3 clinical trial, upadacitnib proved superior to placebo and adalimumab in improving the signs and symptoms of RA in patients on stable background methotrexate.
Interfering with Interferon: Experts Discuss IFN Signaling & IFN Inhibition Treatment Possibilities
NIH investigators describe key features and genetic causes of Mendelian interferonopathies, & treatment approaches that may indicate the efficacy of IFN inhibition.
FDA Provides 2020 Rheumatology Drug Update
Three FDA representatives discuss new drug indications, safety precautions and label changes, & an emergency program to rapidly evaluate existing immunomodulating therapies for use in COVID-19 patients.
COVID-19 Risks & Treatment for Patients with Rheumatic Disease
The Global Rheumatology Alliance is an important tool for assessing COVID-19 risk, & the ACR COVID-19 Task Force provides treatment guidance to rheumatology practitioners.
Top Research in Lupus Presented at ACR Convergence 2020
ACR CONVERGENCE 2020—Held Nov. 5–9, the ACR’s first fully virtual annual meeting is a wrap, but that doesn’t mean it’s too late to catch the highlights. Dozens of research abstracts on various aspects of lupus were presented during the fully virtual event, and David S. Pisetsky, MD, PhD, professor of medicine and immunology at Duke…
Investigation Continues on Repurposed Rheumatology Therapies for COVID-19 Cytokine Storm
Roberto Caricchio, MD, discusses what trials of repurposed rheumatology drugs to treat COVID-19 cytokine storm have shown so far.
The Great Debate: Should Jakinibs Be Used Before Biologics after Methotrexate Failure in RA?
ACR CONVERGENCE 2020—In many ways, the current plethora of treatment options for rheumatoid arthritis patients represents an embarrassment of riches. However, while many therapeutics approved by the U.S. Food & Drug Administration (FDA) are available, knowing the order in which to try these medications with patients can be quite challenging. In The Great Debate, held…
- « Previous Page
- 1
- …
- 4
- 5
- 6
- 7
- 8
- …
- 10
- Next Page »